SG2057 (DRG16) is a PBD dimer containing a pentyldioxy linkage which binds sequence selectively in the minor groove of DNA forming DNA interstrand and intrastrand cross-linked adducts. SG2057 is a highly active antitumor agent In Vitro SG2057 has multilog differential in vitro cytotoxicity against a panel of human tumour cell lines with a mean GI 50 of 212 pM. SG2057 is highly efficient at producing DNA interstrand cross-links in cells which form rapidly and persist over a 48 h period. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo SG2057 (5-60 μg/kg; i.v) exhibits dose-dependent antitumor activity in human tumor xenograft models . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female NCr-nude mice injected with SKOV-3 cells Dosage: 5 μg/kg, 10 μg/kg, 20 μg/kg, 30 μg/kg, 40 μg/kg, 50 μg/kg, 60 μg/kg Administration: i.v.; daily, once a week, or once every four days Result: Showed significant antitumor activity. Form:Solid IC50& Target:Pyrrolobenzodiazepines
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
SG2057
CAS number：260417-62-7 molecular formula：C33H36N4O6
overview
compound introduction
Specs
| Chinese alias | - | ||
| English alias | - | ||
| CAS number | 260417-62-7 | molecular formula | C33H36N4O6 |
| molecular weight | 584.66 g/mol | Exact mass | ≥98% |
| PSA | 102.000 Ų | logp | 2.700 |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
